Drug Profile
Research programme: apolipoprotein E gene therapy - Eli Lilly and Company
Alternative Names: ApoE2 gene therapy - Eli Lilly and CompanyLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Apolipoprotein E agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 04 May 2005 Preclinical trials in Alzheimer's disease in USA (unspecified route)